BioSpace News Archive

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the Phase III POLARIX study showing that treatment with Polivy® (polatuzumab vedotin) in combination with Rituxan® (rituximab) plus cyclophosphamide, doxorubicin and prednisone (R-CHP).

PharmaJet®, the maker of innovative, needle-free injection technology, today announced that one of its pharmaceutical partners, Nykode Therapeutics (formerly Vaccibody) has begun a phase 1/2 clinical trial to specifically address emerging SARS-CoV-2 variants.

India Globalization Capital, Inc. (“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease.

Denovo Biopharma LLC (“Denovo”), a pioneer in applying precision medicine to the development of innovative therapies, today announced its partner Aytu BioPharma (Nasdaq: AYTU), has received FDA clearance for its IND application for enzastaurin and also Orphan Drug Designation (ODD) for enzastaurin for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS).

The Prostate Cancer Foundation announced the Class of 2021 Young Investigator Award recipients totaling nearly $6.5 million in funding for innovative prostate cancer research.

Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), a leading developer of TGF-β therapeutics for oncology and virology, today announced that the Company’s Chief Clinical Officer and Board Director, Dr. Anthony Maida, will present at the upcoming 2nd Annual TGF-β for Immuno-Oncology Drug Development Summit (tgf-beta-summit.com).

The American Urological Association is pleased to announce Jorge Gutiérrez-Aceves, MD has been named by the Board of Directors as AUA Assistant Secretary for the Americas and the Caribbean.

Dr. Yavorsky is a psychologist by training and has worked in clinical trials in the pharmaceutical industry for nearly twenty years.

ANVS401 (Posiphen) Inhibits the Translation of mRNAs of Neurotoxic Proteins Responsible for the Progression of Neurodegenerative Diseases.

Biognosys, and Thermo Fisher Scientific, announced today that they have extended a co-marketing agreement to provide life science researchers with comprehensive mass spectrometry solutions to gain deep proteomics insights at a large scale.